Skip to main content

Qiagen Value Stock - Dividend - Research Selection

Qiagen

ISIN: NL0012169213 , WKN: A2DKCH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

2025-04-01
VENLO, Netherlands, April 01, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria research and surveillance efforts.

Bio-Techne Opens New Customer Experience Centre in Germany

2025-03-31
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

2025-03-31
VENLO, Netherlands, March 31, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

2025-03-28
Qiagen (NYSE:QGEN) has had a rough three months with its share price down 14%. It seems that the market might have...

Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?

2025-03-12
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.

The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses

2025-03-08
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...

Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?

2025-03-07
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B

2025-03-07
This clearance represents the company’s second FDA clearance for a QIAstat-Dx panel this year.

QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel

2025-03-07
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

2025-03-06
GERMANTOWN, Md. & VENLO, Netherlands, March 06, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States.